620,861 Shares in Boston Scientific Corporation $BSX Bought by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab purchased a new position in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 620,861 shares of the medical equipment provider’s stock, valued at approximately $26,498,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Danske Bank A S bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $34,965,000. Diversify Advisory Services LLC bought a new position in shares of Boston Scientific during the second quarter worth about $689,000. Wealthfront Advisers LLC acquired a new position in Boston Scientific in the second quarter worth about $3,253,000. First National Bank of Omaha acquired a new position in Boston Scientific in the second quarter worth about $3,533,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in Boston Scientific in the second quarter valued at about $99,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Citigroup decreased their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Royal Bank Of Canada dropped their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Finally, Canaccord Genuity Group reduced their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Stock Down 1.8%

NYSE:BSX opened at $50.51 on Wednesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $46.15 and a 200-day moving average of $58.50. The firm has a market capitalization of $73.20 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the business posted $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.